Antimalarials may reduce cancer risk in patients with systemic lupus erythematosus: a systematic review and meta-analysis of prospective studies
CONCLUSION: Results of this meta-analysis showed that antimalarial drugs might be protective factors for cancer in SLE. Hydroxychloroquine might be a protective factor for cancer in SLE patients.KEY MESSAGESAntimalarials might be protective factors for cancer in SLE.Hydroxychloroquine might be a protective factor for cancer in SLE patients.The first article to perform the meta-analysis of antimalarial drugs on the risk of cancer in SLE patients.PMID:34553648 | DOI:10.1080/07853890.2021.1981547
Source: Annals of Medicine - Category: Internal Medicine Authors: Xian-Bao Li Nv-Wei Cao Xiu-Jie Chu Hao-Yue Zhou Hua Wang Si-Jie Yu Dong-Qing Ye Bao-Zhu Li Source Type: research
More News: Cancer | Cancer & Oncology | Databases & Libraries | Hydroxychloroquine | Internal Medicine | Lupus | Science | Study